RPL36AP21

Across TCGA pan-cancer cohorts, RPL36AP21 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL36AP21’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL36AP21 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL36AP21 is over-expressed in tumor, although a few such as BRCA and STAD show the opposite, repressed pattern.

BRCA, LIHC, and STAD are the cancer types where RPL36AP21 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL36AP21 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	−0.118	.004	4	view →
LIHC	All	All	+0.111	.005	3	view →
STAD	Male	III,IV	−0.346	.029	2	view →
PRAD	All	All	+0.177	.007	2	view →
KIRC	All	All	+0.151	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL36AP21–BRCA

Open the BRCA breakdown →